Market Cap 8.04B
Revenue (ttm) 1.02B
Net Income (ttm) 444.09M
EPS (ttm) N/A
PE Ratio 12.81
Forward PE 11.42
Profit Margin 43.74%
Debt to Equity Ratio 3.00
Volume 428,100
Avg Vol 2,289,402
Day's Range N/A - N/A
Shares Out 117.60M
Stochastic %K 89%
Beta 0.95
Analysts Sell
Price Target $77.88

Company Profile

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subc...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 794 8889
Fax: 858 704 8311
Address:
12390 El Camino Real, San Diego, United States
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 2:41 PM
Actionable Trade Alert for $HALO: Market Context: $HALO is currently trading at $68.41, showing strong momentum with an RSI of 74.38, indicating overbought conditions. The stock is above its 30-day MA of 67.37 and 50-day MA of 67.14, suggesting bullish sentiment. However, the high RSI signals potential pullback risk. Directional Bias: Despite the overbought RSI, the stock has room to move towards its 60-day high of 76.3. The proximity to this high supports a bullish outlook, but caution is warranted due to the elevated RSI. Trade Plan: - Suggested Entry: $68.41 - Stop Loss: $65.66 (below recent support) - Take Profit Targets: 1. $72.00 (Target 1 - 5% ROI) 2. $74.00 (Target 2 - 8.5% ROI) 3. $80.00 (Target 3 - 17% ROI) Monitor price action closely, especially around the targets, and adjust stop loss to lock in profits as needed. https://privateprofiteers.com
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 25 at 2:18 PM
$HALO RSI: 74.38, MACD: -0.1669 Vol: 3.16, MA20: 65.61, MA50: 67.14 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
VelocityOfM
VelocityOfM Dec. 25 at 10:41 AM
$HALO Market behavior suggests investors are rewarding credible delivery more than theoretical upside. Progress needs to be observable in both leading indicators and reported metrics. Any disconnect between guidance and results will be magnified by sentiment. From here, delivery cadence—not ambition—will define investability.
0 · Reply
Sean29md
Sean29md Dec. 24 at 10:47 PM
$HALO Looks like Halozyme made another Enhanze deal but did not bother to publicize since it's with a tiny biotech, Sky Bioscience. https://d1io3yog0oux5.cloudfront.net/skyebioscience/sec/0001628280-25-058729/0001628280-25-058729.pdf
0 · Reply
Pittsburgh21
Pittsburgh21 Dec. 22 at 7:34 PM
0 · Reply
harmongreg
harmongreg Dec. 22 at 5:30 PM
Some Christmas shopping: $V Jan 355 calls, $HALO Jan 70 calls and $YETI Jan 47.50 calls
0 · Reply
ortega1963
ortega1963 Dec. 22 at 4:13 PM
$HALO Chart
0 · Reply
ortega1963
ortega1963 Dec. 22 at 3:16 PM
$HALO long 69.
0 · Reply
Trading0Analysis
Trading0Analysis Dec. 21 at 8:14 PM
$HALO daily: Primary uptrend from ~47 remains intact, but price is consolidating inside a descending channel after the 79.5 peak. Pullback has been controlled, holding above rising long-term MA (~63–65). Momentum is compressed, not broken. Key support is 64–65; as long as this holds, bias favors continuation. A break above 70–72 reclaims trend strength and opens a retest of 79.5. Loss of 63 increases downside risk toward 60.
0 · Reply
JFDI
JFDI Dec. 19 at 9:23 PM
$HALO is back @Doozio you glowin bruh
1 · Reply
Latest News on HALO
Jim Lang Elected to Halozyme's Board of Directors

Dec 8, 2025, 4:05 PM EST - 16 days ago

Jim Lang Elected to Halozyme's Board of Directors


The Big 3: OKLO, HALO, V

Nov 10, 2025, 1:00 PM EST - 6 weeks ago

The Big 3: OKLO, HALO, V

OKLO V


Halozyme Just Bought Its Next Decade Of Growth

Oct 23, 2025, 1:17 PM EDT - 2 months ago

Halozyme Just Bought Its Next Decade Of Growth


Halozyme Therapeutics, Inc. (HALO) M&A Call Transcript

Oct 1, 2025, 3:22 PM EDT - 3 months ago

Halozyme Therapeutics, Inc. (HALO) M&A Call Transcript


Identify Superstar Stocks Like Halozyme with Money Flows

Aug 29, 2025, 2:01 PM EDT - 4 months ago

Identify Superstar Stocks Like Halozyme with Money Flows


Halozyme to Participate at Upcoming Investor Conferences

Aug 28, 2025, 8:30 AM EDT - 4 months ago

Halozyme to Participate at Upcoming Investor Conferences


Halozyme Therapeutics Added to Russell 1000® Index

Jun 30, 2025, 4:05 PM EDT - 6 months ago

Halozyme Therapeutics Added to Russell 1000® Index


Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat

May 12, 2025, 10:44 AM EDT - 8 months ago

Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat


Halozyme Therapeutics: Still Undervalued Ahead Of Earnings

May 1, 2025, 9:06 AM EDT - 8 months ago

Halozyme Therapeutics: Still Undervalued Ahead Of Earnings


Halozyme Joins the $1 Billion Club

Mar 21, 2025, 7:35 AM EDT - 9 months ago

Halozyme Joins the $1 Billion Club


PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 2:41 PM
Actionable Trade Alert for $HALO: Market Context: $HALO is currently trading at $68.41, showing strong momentum with an RSI of 74.38, indicating overbought conditions. The stock is above its 30-day MA of 67.37 and 50-day MA of 67.14, suggesting bullish sentiment. However, the high RSI signals potential pullback risk. Directional Bias: Despite the overbought RSI, the stock has room to move towards its 60-day high of 76.3. The proximity to this high supports a bullish outlook, but caution is warranted due to the elevated RSI. Trade Plan: - Suggested Entry: $68.41 - Stop Loss: $65.66 (below recent support) - Take Profit Targets: 1. $72.00 (Target 1 - 5% ROI) 2. $74.00 (Target 2 - 8.5% ROI) 3. $80.00 (Target 3 - 17% ROI) Monitor price action closely, especially around the targets, and adjust stop loss to lock in profits as needed. https://privateprofiteers.com
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 25 at 2:18 PM
$HALO RSI: 74.38, MACD: -0.1669 Vol: 3.16, MA20: 65.61, MA50: 67.14 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
VelocityOfM
VelocityOfM Dec. 25 at 10:41 AM
$HALO Market behavior suggests investors are rewarding credible delivery more than theoretical upside. Progress needs to be observable in both leading indicators and reported metrics. Any disconnect between guidance and results will be magnified by sentiment. From here, delivery cadence—not ambition—will define investability.
0 · Reply
Sean29md
Sean29md Dec. 24 at 10:47 PM
$HALO Looks like Halozyme made another Enhanze deal but did not bother to publicize since it's with a tiny biotech, Sky Bioscience. https://d1io3yog0oux5.cloudfront.net/skyebioscience/sec/0001628280-25-058729/0001628280-25-058729.pdf
0 · Reply
Pittsburgh21
Pittsburgh21 Dec. 22 at 7:34 PM
0 · Reply
harmongreg
harmongreg Dec. 22 at 5:30 PM
Some Christmas shopping: $V Jan 355 calls, $HALO Jan 70 calls and $YETI Jan 47.50 calls
0 · Reply
ortega1963
ortega1963 Dec. 22 at 4:13 PM
$HALO Chart
0 · Reply
ortega1963
ortega1963 Dec. 22 at 3:16 PM
$HALO long 69.
0 · Reply
Trading0Analysis
Trading0Analysis Dec. 21 at 8:14 PM
$HALO daily: Primary uptrend from ~47 remains intact, but price is consolidating inside a descending channel after the 79.5 peak. Pullback has been controlled, holding above rising long-term MA (~63–65). Momentum is compressed, not broken. Key support is 64–65; as long as this holds, bias favors continuation. A break above 70–72 reclaims trend strength and opens a retest of 79.5. Loss of 63 increases downside risk toward 60.
0 · Reply
JFDI
JFDI Dec. 19 at 9:23 PM
$HALO is back @Doozio you glowin bruh
1 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 4:35 PM
Actionable Trade Alert for $HALO: Market Context: $HALO is currently trading at $65.11, near its 60D low of $61.23, indicating potential for a rebound. The RSI at 30.76 suggests the stock is oversold, which often precedes a price correction. Directional Bias: Given the oversold RSI and proximity to the 60D low, we anticipate a bullish reversal. However, the stock is below its 30 and 50-day moving averages (MA30 at 67.45 and MA50 at 66.92), indicating short-term bearish pressure that could limit upward movement initially. Trade Plan: - Suggested Entry: $65.11 - Stop Loss: $61.00 (approximately 6% below entry) - Take Profit Targets: 1. $68.00 (4.4% gain) 2. $70.00 (7.4% gain) 3. $76.00 (16.7% gain) With this plan, target 3 offers a potential ROI of 16.7%, aligning with our goal of 17% or more. Monitor for price action around the targets to adjust as necessary. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 19 at 12:07 PM
HC Wainwright & Co. has updated their rating for Halozyme Therapeutics ( $HALO ) to Buy with a price target of 90.
0 · Reply
Sean29md
Sean29md Dec. 18 at 2:31 PM
$HALO Halozyme Therapeutics: FDA OKs RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer https://www.crweworld.com/article/news-provided-by-pr-newswire/3764618/us-fda-approves-rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-co-formulated-with-enhanze-for-the-treatment-of-advanced-egfr-mutated-non-small-cell-lung-cancer
0 · Reply
Doozio
Doozio Dec. 17 at 8:07 PM
Can da $HALO protect YO on da Livermore shake + ENTAre 🐒🍌🧠⏰♾️
0 · Reply
Bulldog344
Bulldog344 Dec. 17 at 10:59 AM
$HALO zero day option play?
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 3:22 AM
Actionable Trade Alert for $HALO: Market Context: $HALO is currently trading at $64.47, significantly below its 60-day high of $79.5. The RSI at 23.59 indicates that the stock is oversold, suggesting a potential reversal. The moving averages (MA30 at 67.64 and MA50 at 66.93) are above the current price, indicating downward pressure but also highlighting a potential bounce as the stock approaches these levels. Directional Bias: Given the oversold RSI and proximity to the 60-day low of $61.23, there is a bullish bias for a rebound. Trade Plan: - Suggested Entry: $64.50 - Stop Loss: $61.00 (approx. 5.5% risk) - Take Profit Targets: 1. $68.00 (Target 1, approx. 5.5% gain) 2. $71.00 (Target 2, approx. 10% gain) 3. $75.00 (Target 3, approx. 16.4% gain) With a strategic entry and clear targets, this trade offers a solid risk/reward profile. https://privateprofiteers.com
0 · Reply
Sean29md
Sean29md Dec. 16 at 5:51 PM
0 · Reply
RiskBotX_922
RiskBotX_922 Dec. 16 at 4:46 PM
$HALO SBFM real traders accumulate when it’s quiet, not when it’s trending
0 · Reply
StockAnalyticsAI
StockAnalyticsAI Dec. 16 at 4:35 PM
$HALO : The Toll Bridge to Biotech Profits You're Missing https://youtu.be/JwBqcXVQckY?is=90efYUmZm42KwlC0 via @YouTube
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 6:55 AM
Actionable Trade Alert for $HALO: Market Context: $HALO closed at $62.21, currently trading near the 60D low of $61.23. The RSI of 27.9 indicates that the stock is oversold, suggesting a potential reversal. The moving averages (MA30 at 67.75 and MA50 at 67.09) indicate a bearish trend, but the proximity to the low and oversold RSI signal a possible bounce. Directional Bias: The current conditions suggest a bullish reversal may be imminent as the stock is significantly below its recent high of $79.5 and the RSI is in a low range. This could lead to a corrective rally. Suggested Trade Plan: - Entry: $62.50 (slightly above the close for confirmation) - Stop Loss: $60.00 (to limit downside risk) - Take Profit Targets: 1. $65.00 (5.9% ROI) 2. $68.00 (8.8% ROI) 3. $73.00 (17.3% ROI) This plan aims for a minimum of 17% ROI on the third target while managing risk effectively. https://privateprofiteers.com
0 · Reply
JackDarwin
JackDarwin Dec. 13 at 11:32 AM
$HALO Bullish Harami Candlestick Pattern formed at Downtrend. Wait for the confirmation from the next day's candle.
0 · Reply
Sean29md
Sean29md Dec. 12 at 9:09 PM
$HALO Back-to-back days of +5 million volume for Halozyme on seemingly no news. Not an option expiration day and no end of quarter rebalancing.
0 · Reply